- Home
- QURE vs CII Comparison
QURE vs CII Comparison
Compare QURE & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- CII
- Stock Information
- Founded
- QURE 1998
- CII 2004
- Country
- QURE Netherlands
- CII United States
- Employees
- QURE N/A
- CII N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- CII Investment Bankers/Brokers/Service
- Sector
- QURE Health Care
- CII Finance
- Exchange
- QURE Nasdaq
- CII Nasdaq
- Market Cap
- QURE 750.6M
- CII 860.9M
- IPO Year
- QURE 2007
- CII N/A
- Fundamental
- Price
- QURE $16.98
- CII $19.82
- Analyst Decision
- QURE Strong Buy
- CII
- Analyst Count
- QURE 8
- CII 0
- Target Price
- QURE $32.43
- CII N/A
- AVG Volume (30 Days)
- QURE 4.7M
- CII 78.8K
- Earning Date
- QURE 11-05-2024
- CII 01-01-0001
- Dividend Yield
- QURE N/A
- CII 6.17%
- EPS Growth
- QURE N/A
- CII N/A
- EPS
- QURE N/A
- CII N/A
- Revenue
- QURE $28,587,000.00
- CII N/A
- Revenue This Year
- QURE $150.65
- CII N/A
- Revenue Next Year
- QURE N/A
- CII N/A
- P/E Ratio
- QURE N/A
- CII N/A
- Revenue Growth
- QURE N/A
- CII N/A
- 52 Week Low
- QURE $3.73
- CII $16.76
- 52 Week High
- QURE $17.71
- CII $19.81
- Technical
- Relative Strength Index (RSI)
- QURE 75.89
- CII 45.22
- Support Level
- QURE $14.68
- CII $19.44
- Resistance Level
- QURE $17.71
- CII $20.46
- Average True Range (ATR)
- QURE 1.58
- CII 0.25
- MACD
- QURE 0.64
- CII -0.08
- Stochastic Oscillator
- QURE 93.71
- CII 37.25
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.